NTRA - Natera, Inc.

Insider Sale by Fesko John (Pres, CHIEF BUS. OFFICER)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Fesko John, serving as Pres, CHIEF BUS. OFFICER at Natera, Inc. (NTRA), sold 1,688 shares at $204.10 per share, for a total transaction value of $344,517.00. Following this transaction, Fesko John now holds 187,511 shares of NTRA.

This sale represents a 1.00% decrease in Fesko John's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 27, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, April 29, 2026, 2 days after the trade was made.

Natera, Inc. operates in the HEALTHCARE sector, specifically within the DIAGNOSTICS & RESEARCH industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Fesko John

Fesko John

Pres, CHIEF BUS. OFFICER

John Fesko is the President and Chief Business Officer at Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing for oncology, women’s health, and organ health.[[1]](https://www.natera.com/company/news/natera-announces-senior-leadership-appointments/)[[2]](https://www.natera.com/company/leadership-team/)[[3]](https://theorg.com/org/natera/org-chart/john-fesko) In this role, he oversees critical functions including reimbursement strategy and market access, patient operations and experience, marketing and communications, government affairs, business and market development, pharmaceutical services, and international commercial operations and strategy.[[1]](https://www.natera.com/company/news/natera-announces-senior-leadership-appointments/)[[2]](https://www.natera.com/company/leadership-team/) Fesko was promoted to this position in September 2023, having previously served as Chief Business Officer since 2019.[[1]](https://www.natera.com/company/news/natera-announces-senior-leadership-appointments/) Fesko joined Natera in 2014, advancing through several leadership roles of increasing responsibility.[[1]](https://www.natera.com/company/news/natera-announces-senior-leadership-appointments/)[[2]](https://www.natera.com/company/leadership-team/) Prior to Natera, he held positions at Roche, Novartis Pharma AG, MPM Capital, and InVivoScribe, gaining extensive experience in business development, strategic planning, and product management.[[1]](https://www.natera.com/company/news/natera-announces-senior-leadership-appointments/)[[2]](https://www.natera.com/company/leadership-team/) He holds an M.B.A. from MIT and a B.S. in biochemistry and economics from the University of Notre Dame.[[1]](https://www.natera.com/company/news/natera-announces-senior-leadership-appointments/)[[2]](https://www.natera.com/company/leadership-team/)

View full insider profile →

Trade Price

$204.10

Quantity

1,688

Total Value

$344,517.00

Shares Owned

187,511

Trade Date

Monday, April 27, 2026

4 days ago

SEC Filing Date

Wednesday, April 29, 2026

Filed 2 days after trade

HEALTHCAREDIAGNOSTICS & RESEARCH

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning NTRA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6057556

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime